ZNF445

Summary

ZNF445 (zinc finger protein 445, HGNC:21018) is a protein-coding gene on chromosome 3p21.31, encoding Zinc finger protein 445 (P59923). Transcription regulator required to maintain maternal and paternal gene imprinting, a process by which gene expression is restricted in a parent of origin-specific manner by epigenetic modification of genomic DNA and chromatin, including DNA methylation.

Enables double-stranded methylated DNA binding activity. Involved in epigenetic programing of female pronucleus and negative regulation of gene expression via chromosomal CpG island methylation. Located in nucleus.

Source: NCBI Gene 353274 — RefSeq curated summary.

At a glance

• Gene–disease (curated): syndromic disease (Limited, GenCC)
• Clinical variants (ClinVar): 149 total
• MANE Select transcript: NM_181489

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21018
Approved symbol	ZNF445
Name	zinc finger protein 445
Location	3p21.31
Locus type	gene with protein product
Status	Approved
Aliases	ZKSCAN15, ZSCAN47
Ensembl gene	ENSG00000185219
Ensembl biotype	protein_coding
OMIM	619508
Entrez	353274

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 2 retained_intron

ENST00000396077, ENST00000425708, ENST00000460529, ENST00000474600, ENST00000924004, ENST00000924005, ENST00000924006, ENST00000924007, ENST00000924008

RefSeq mRNA: 2 — MANE Select: NM_181489 NM_001369454, NM_181489

CCDS: CCDS2713

Canonical transcript exons

ENST00000396077 — 8 exons

Exon	Start	End
ENSE00001078410	44449513	44449623
ENSE00001523776	44431705	44448739
ENSE00001620076	44477591	44477670
ENSE00001701424	44458244	44458364
ENSE00001726926	44450447	44450573
ENSE00003545483	44451314	44451482
ENSE00003638568	44450868	44450962
ENSE00003690690	44455121	44455696

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 88.25.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.0611 / max 68.7528, expressed in 1588 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
41855	5.0611	1588

Top tissues by expression

133 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	88.25	gold quality
ganglionic eminence	UBERON:0004023	85.27	gold quality
ventricular zone	UBERON:0003053	82.79	gold quality
skeletal muscle tissue	UBERON:0001134	80.61	gold quality
stromal cell of endometrium	CL:0002255	80.33	gold quality
colonic epithelium	UBERON:0000397	80.08	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.56	gold quality
endometrium	UBERON:0001295	78.43	gold quality
muscle tissue	UBERON:0002385	78.43	gold quality
cerebellum	UBERON:0002037	77.77	gold quality
cerebellar cortex	UBERON:0002129	77.72	gold quality
cerebellar hemisphere	UBERON:0002245	77.66	gold quality
ovary	UBERON:0000992	77.32	gold quality
left ovary	UBERON:0002119	77.18	gold quality
tonsil	UBERON:0002372	77.04	gold quality
right hemisphere of cerebellum	UBERON:0014890	77.01	gold quality
urinary bladder	UBERON:0001255	76.35	gold quality
uterine cervix	UBERON:0000002	76.11	gold quality
right ovary	UBERON:0002118	76.05	gold quality
islet of Langerhans	UBERON:0000006	75.97	gold quality
body of uterus	UBERON:0009853	75.95	gold quality
myometrium	UBERON:0001296	75.89	gold quality
mucosa of stomach	UBERON:0001199	75.88	gold quality
smooth muscle tissue	UBERON:0001135	75.85	gold quality
muscle of leg	UBERON:0001383	75.84	gold quality
hindlimb stylopod muscle	UBERON:0004252	75.48	gold quality
corpus callosum	UBERON:0002336	75.46	gold quality
gastrocnemius	UBERON:0001388	75.32	gold quality
endocervix	UBERON:0000458	75.28	gold quality
blood	UBERON:0000178	75.08	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.67

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
AP1

miRNA regulators (miRDB)

233 targeting ZNF445, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	prdm2a	ENSDARG00000090721
mus_musculus	Zfp445	ENSMUSG00000047036
rattus_norvegicus	Zfp445	ENSRNOG00000025554
drosophila_melanogaster	CG12769	FBGN0033252
caenorhabditis_elegans		WBGENE00001223
caenorhabditis_elegans		WBGENE00017406
caenorhabditis_elegans		WBGENE00019960

Paralogs (7): ZNF423 (ENSG00000102935), ZNF211 (ENSG00000121417), ZNF462 (ENSG00000148143), ZBTB39 (ENSG00000166860), ZNF597 (ENSG00000167981), ZNF786 (ENSG00000197362), ZNF521 (ENSG00000198795)

Protein

Protein identifiers

Zinc finger protein 445 — P59923 (reviewed: P59923)

Alternative names: Zinc finger protein 168, Zinc finger protein with KRAB and SCAN domains 15

All UniProt accessions (2): B7ZKX2, P59923

UniProt curated annotations — full annotation on UniProt →

Function. Transcription regulator required to maintain maternal and paternal gene imprinting, a process by which gene expression is restricted in a parent of origin-specific manner by epigenetic modification of genomic DNA and chromatin, including DNA methylation. Acts by controlling DNA methylation during the earliest multicellular stages of development at multiple imprinting control regions (ICRs). Acts together with ZFP57, but seems to be the major factor in human early embryonic imprinting maintenance. In contrast, in mice, ZFP57 plays the predominant role in imprinting maintenance.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (2): NP_001356383, NP_852466* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR003309	SCAN_dom	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR038269	SCAN_sf	Homologous_superfamily

Pfam: PF00096, PF01352, PF02023

UniProt features (33 total): zinc finger region 14, cross-link 12, domain 2, region of interest 2, chain 1, compositionally biased region 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P59923-F1	57.22	0.01

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (12): 28, 317, 374, 375, 399, 567, 654, 736, 758, 938, 956, 975

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 64 (showing top): GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, STARK_HYPPOCAMPUS_22Q11_DELETION_UP, MARTINEZ_RB1_TARGETS_UP, GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC, WANG_LMO4_TARGETS_DN, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, GOBP_CHROMATIN_REMODELING, MARTINEZ_RB1_AND_TP53_TARGETS_UP, GOBP_EPIGENETIC_REGULATION_OF_GENE_EXPRESSION, TGGAAA_NFAT_Q4_01, GOMF_CHROMATIN_BINDING, DODD_NASOPHARYNGEAL_CARCINOMA_DN, GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN, GOMF_DOUBLE_STRANDED_METHYLATED_DNA_BINDING, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_UP

GO Biological Process (4): regulation of transcription by RNA polymerase II (GO:0006357), negative regulation of gene expression via chromosomal CpG island methylation (GO:0044027), epigenetic programing of female pronucleus (GO:0044726), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (6): chromatin binding (GO:0003682), zinc ion binding (GO:0008270), double-stranded methylated DNA binding (GO:0010385), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
negative regulation of gene expression, epigenetic	1
epigenetic programming in the zygotic pronuclei	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
transition metal ion binding	1
double-stranded DNA binding	1
nucleic acid binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

734 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF445	TRIM28	Q13263	699
ZNF445	SETDB1	Q15047	657
ZNF445	ZDBF2	Q9HCK1	546
ZNF445	SLC38A4	Q969I6	511
ZNF445	TMEM235	A6NFC5	488
ZNF445	CIMIP2B	A8MTA8	443
ZNF445	G5EA03	G5EA03	434
ZNF445	CFAP96	A7E2U8	432
ZNF445	PTPN23	Q9H3S7	425
ZNF445	NAP1L5	Q96NT1	424
ZNF445	MEST	Q5EB52	411
ZNF445	BAZ1B	Q9UIG0	394
ZNF445	KAT8	Q9H7Z6	383
ZNF445	DLK1	P15803	380
ZNF445	IGF2	P01344	378

IntAct

86 interactions, top by confidence:

A	B	Type	Score
ZNF396	ZNF24	psi-mi:“MI:0914”(association)	0.700
ZNF169	ZNF316	psi-mi:“MI:0914”(association)	0.530
ZNF324B	ZNF316	psi-mi:“MI:0914”(association)	0.530
ZNF707	ZNF316	psi-mi:“MI:0914”(association)	0.530
CACNG5	ZNF316	psi-mi:“MI:0914”(association)	0.530
ZNF483	ZNF197	psi-mi:“MI:0914”(association)	0.530
ZNF71	NVL	psi-mi:“MI:0914”(association)	0.530
SYT12	B4GALT5	psi-mi:“MI:0914”(association)	0.530
CCDC6	LZTS3	psi-mi:“MI:0914”(association)	0.530
CBX5	WIZ	psi-mi:“MI:0914”(association)	0.530
TRIM28	ZNF320	psi-mi:“MI:0914”(association)	0.530
RPS3	ZNF316	psi-mi:“MI:0914”(association)	0.530
TIMM50	ZNF724	psi-mi:“MI:0914”(association)	0.530
ZNF396	ZNF24	psi-mi:“MI:0914”(association)	0.530
ZNF263	AHCYL1	psi-mi:“MI:0914”(association)	0.530
NDEL1	OFD1	psi-mi:“MI:0914”(association)	0.530
Cbx1		psi-mi:“MI:0914”(association)	0.350
Set	ZKSCAN1	psi-mi:“MI:0914”(association)	0.350

BioGRID (85): ZNF445 (Affinity Capture-MS), ZNF445 (Affinity Capture-MS), ZNF445 (Affinity Capture-MS), ZNF445 (Affinity Capture-MS), ZNF445 (Affinity Capture-MS), ZNF445 (Affinity Capture-MS), ZNF445 (Affinity Capture-MS), ZNF445 (Affinity Capture-MS), ZNF445 (Affinity Capture-MS), ZNF445 (Affinity Capture-MS), ZNF445 (Affinity Capture-MS), ZNF445 (Affinity Capture-MS), ZNF445 (Affinity Capture-MS), ZNF445 (Affinity Capture-MS), ZNF445 (Affinity Capture-MS)

ESM2 similar proteins: A1YEQ3, A1YEV9, A1YFW6, A1YG26, A1YG48, A1YG60, A2T6W2, A2T712, A2T736, A2T7L7, A6QNZ0, O14978, O15535, O95125, P17022, P17029, P49910, P51815, P59923, Q07231, Q15776, Q16670, Q1LZ87, Q3MJ62, Q3URR7, Q4KLI1, Q4R8H9, Q53GI3, Q5R670, Q5R741, Q5RJ54, Q63HK3, Q642B9, Q6P9G9, Q810A1, Q86W11, Q8BGS3, Q8CF60, Q8NF99, Q92670

Diamond homologs: A1YEP8, A1YEQ3, A1YEV9, A1YFW2, A1YFW6, A1YG26, A1YG48, A1YG60, A1YGJ4, A1YGK6, A2T6E3, A2T6V8, A2T6W2, A2T712, A2T736, A2T7D2, A2T7D7, A2T7F2, A2T7F4, A2T7L7, A2T812, A6QNZ0, A6QPT6, B2KFW1, O14709, O14771, O14978, O15535, O43309, O60304, O95125, P10073, P17022, P17028, P17029, P17040, P28698, P49910, P51815, P59923

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

149 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	127
Likely benign	7
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1425 predictions. Top by Δscore:

Variant	Effect	Δscore
3:44449508:CTCA:C	donor_loss	1.0000
3:44449509:TCA:T	donor_loss	1.0000
3:44449510:CA:C	donor_loss	1.0000
3:44449511:ACCTG:A	donor_loss	1.0000
3:44449619:TCCCA:T	acceptor_gain	1.0000
3:44449620:CCCA:C	acceptor_gain	1.0000
3:44449620:CCCAC:C	acceptor_gain	1.0000
3:44449621:CCA:C	acceptor_gain	1.0000
3:44449621:CCAC:C	acceptor_gain	1.0000
3:44449622:CA:C	acceptor_gain	1.0000
3:44449622:CAC:C	acceptor_gain	1.0000
3:44449622:CACT:C	acceptor_loss	1.0000
3:44449623:ACT:A	acceptor_loss	1.0000
3:44449624:C:CC	acceptor_gain	1.0000
3:44449624:CT:C	acceptor_loss	1.0000
3:44449625:T:A	acceptor_loss	1.0000
3:44449627:C:CT	acceptor_gain	1.0000
3:44450442:CTT:C	donor_loss	1.0000
3:44450443:TTACC:T	donor_loss	1.0000
3:44450444:TA:T	donor_loss	1.0000
3:44450445:AC:A	donor_gain	1.0000
3:44450445:ACCC:A	donor_loss	1.0000
3:44450446:C:CG	donor_loss	1.0000
3:44450446:CC:C	donor_gain	1.0000
3:44449511:A:AC	donor_gain	0.9900
3:44449512:C:CC	donor_gain	0.9900
3:44449628:A:T	acceptor_gain	0.9900
3:44450441:ACTT:A	donor_loss	0.9900
3:44450445:A:AC	donor_gain	0.9900
3:44450446:C:CC	donor_gain	0.9900

AlphaMissense

6867 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:44446626:G:C	F1015L	0.997
3:44446626:G:T	F1015L	0.997
3:44446628:A:G	F1015L	0.997
3:44447274:G:C	F799L	0.997
3:44447274:G:T	F799L	0.997
3:44447276:A:G	F799L	0.997
3:44447063:A:G	C870R	0.996
3:44447124:A:C	F849L	0.996
3:44447124:A:T	F849L	0.996
3:44447126:A:G	F849L	0.996
3:44447601:A:C	F690L	0.996
3:44447601:A:T	F690L	0.996
3:44447603:A:G	F690L	0.996
3:44448105:G:C	F522L	0.996
3:44448105:G:T	F522L	0.996
3:44448107:A:G	F522L	0.996
3:44447013:A:C	H886Q	0.994
3:44447013:A:T	H886Q	0.994
3:44447358:G:C	F771L	0.994
3:44447358:G:T	F771L	0.994
3:44447360:A:G	F771L	0.994
3:44447517:A:C	F718L	0.994
3:44447517:A:T	F718L	0.994
3:44447519:A:G	F718L	0.994
3:44448021:G:C	F550L	0.994
3:44448021:G:T	F550L	0.994
3:44448023:A:G	F550L	0.994
3:44446956:G:C	F905L	0.993
3:44446956:G:T	F905L	0.993
3:44446958:A:G	F905L	0.993

dbSNP variants (sampled 300 via entrez): RS1000138890 (3:44439464 T>C), RS1000146830 (3:44475600 G>C,T), RS1000248826 (3:44444126 C>A,T), RS1000297945 (3:44444376 G>A,C), RS1000327244 (3:44457549 A>G), RS1000557488 (3:44463034 T>C), RS1000565326 (3:44432575 C>A), RS1000744207 (3:44437710 A>C), RS1000747768 (3:44436343 T>C), RS1000875844 (3:44461120 T>A,C), RS1001013757 (3:44442069 A>C), RS1001060626 (3:44449342 G>A,C), RS1001113108 (3:44449033 C>G), RS1001197861 (3:44438130 G>A), RS1001242554 (3:44465220 A>G)

Disease associations

OMIM: gene MIM:619508 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
syndromic disease	Limited	Autosomal recessive

Mondo (1): syndromic disease (MONDO:0002254)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D013577	Syndrome	C23.550.288.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases expression, increases methylation	2
TAK-243	increases sumoylation	1
dicrotophos	increases expression	1
terbufos	decreases methylation	1
CGP 52608	affects binding, increases reaction	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Acetaminophen	increases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Fonofos	decreases methylation	1
Parathion	decreases methylation	1
Plant Extracts	affects cotreatment, increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1
Antirheumatic Agents	increases expression	1

Clinical trials (associated diseases)

25 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00027456	PHASE2	COMPLETED	Leptin to Treat Severe Insulin Resistance - Pilot Study
NCT00213447	Not specified	COMPLETED	T Cell Response in Hypersensitivity Syndrome
NCT02240888	Not specified	COMPLETED	Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response
NCT02526082	Not specified	ACTIVE_NOT_RECRUITING	Long-term Follow-up of the Helsinki Businessmen Study
NCT02637518	Not specified	UNKNOWN	Comprehensive Validation of Frailty Assessment Tools in Older Adults in Different Clinical and Social Settings
NCT02971072	Not specified	COMPLETED	Neurophysiology of Weakness and Exercise in Rotator Cuff Tendinopathy
NCT02974569	Not specified	COMPLETED	Improving Symptom Self-management in Adolescents & Young Adults With Cancer
NCT03265561	Not specified	COMPLETED	Spinal Infection Management With Structural Allograft
NCT04190342	Not specified	COMPLETED	Effects of a Traditional Chinese Exercise Program on Symptom Cluster in Breast Cancer Patients
NCT04874584	Not specified	COMPLETED	Culturally Tailored Nurse Coaching Study for Cancer Symptom Management
NCT04909489	Not specified	UNKNOWN	PDR and SKYD of Dyslipidemia’s Characteristics From the Oxidative Stress Enhancement Caused by Inhibition of Serine Metabolic Pathway
NCT05218122	Not specified	UNKNOWN	Characteristics of LKDS and PBSS of KOA Based on the Enhancement of Inflammatory Response by TGF-β/Smad Pathway Inhibited
NCT05266118	Not specified	COMPLETED	Patient Reported Symptoms the First Week After Intensive Care Unit Discharge and up to Hospital Discharge
NCT05321966	Not specified	COMPLETED	The Effect of Video Training on Symptom Burden Patients Undergoing Hemodialysis Treatment
NCT05818748	Not specified	UNKNOWN	Effect Of Virtual Reality Distraction on Symptom Control and Anxiety in Children With Leukemia
NCT05837988	Not specified	UNKNOWN	Construction of Symptom Network in Maintenance Hemodialysis Patients
NCT06143436	Not specified	UNKNOWN	TCM Constitution, Pattern Types, and Disease Factors in Primary Lung Cancer.
NCT06222008	Not specified	UNKNOWN	Study on Symptom Clusters During Chemotherapy in Ovarian Cancer Patients With Different Chinese Medicine Constitution
NCT06412107	Not specified	COMPLETED	Somatic Acupressure for Symptom Cluster Management in Breast Cancer Survivors
NCT06847360	Not specified	RECRUITING	Home-based Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for IBS Pain
NCT07281300	Not specified	RECRUITING	Mindfulness-Oriented Respiratory Distress Symptom Intervention for Lung Cancer
NCT07315672	Not specified	RECRUITING	Acupressure for Cough in Lung Cancer Survivors
NCT07479654	Not specified	NOT_YET_RECRUITING	AI-Enabled Frailty Risk Prediction in Adult Congenital Heart Disease
NCT07495358	Not specified	NOT_YET_RECRUITING	Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cancer Undergoing Chemotherapy
NCT07576114	Not specified	RECRUITING	Comparison of Gluteal Muscle Activation and Core Strengthening in Dead Butt Syndrome Syndrome